Pliant Therapeutics Income Statement (2019-2025) | PLRX

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 28.94M3.60M4.81M4.42M2.17M1.79M1.61M2.00M1.25M4.99M1.48M1.97M1.33M0.25M-0.80M-0.81M-0.81M
Operating items
Research & Development 13.92M17.54M16.88M17.85M18.53M19.22M21.05M18.75M20.88M26.34M24.61M25.11M29.27M33.00M32.34M33.18M37.15M45.62M47.75M38.79M43.44M32.20M17.94M
Selling, General & Administrative 4.01M3.04M4.59M5.63M6.57M5.47M7.67M7.85M8.58M8.30M8.82M14.25M14.15M14.57M15.35M13.85M15.25M15.02M14.26M14.53M15.50M13.39M10.33M
Operating Expenses 17.93M20.58M21.48M23.48M25.09M24.69M28.72M26.60M29.46M34.63M33.43M39.37M43.43M47.58M47.69M47.04M52.39M60.64M62.01M53.32M58.94M45.59M28.27M
Operating Income 11.01M-16.98M-16.66M-19.02M-22.92M-22.90M-27.11M-24.60M-28.21M-29.64M-31.95M-37.40M-42.09M-47.33M-47.69M-47.04M-52.39M-60.64M-62.01M-53.32M-58.94M-45.59M-28.27M
EBIT 11.01M-16.98M-16.66M-19.02M-22.92M-22.90M-27.11M-24.60M-28.21M-29.64M-31.95M-37.40M-42.09M-47.33M-47.69M-47.04M-52.39M-60.64M-62.01M-53.32M-58.94M-45.59M-28.27M
Non-operating items
Interest & Investment Income 0.02M-0.03M0.13M-0.01M0.06M0.07M0.07M0.07M0.11M0.27M1.63M2.66M4.86M6.46M6.51M6.25M5.88M5.65M5.13M4.42M3.57M3.10M2.78M
Other Non Operating Income -0.14M0.06M-0.10M
Non Operating Income -0.14M0.06M-0.10M
Net income details
EBT 11.03M-17.00M-16.53M-19.03M-22.86M-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M
Profit After Tax 11.03M-17.00M-16.53M-19.03M-22.86M-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M
Income from Continuing Operations 11.03M-17.00M-16.53M-19.03M-22.86M-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M
Consolidated Net Income 11.03M-17.00M-16.53M-19.03M-22.86M-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M
Income towards Parent Company 11.03M-17.00M-16.53M-19.03M-22.86M-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M
Preferred Dividend Payments 11.03M
Net Income towards Common Stockholders -17.00M-16.53M-19.03M-22.86M-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M
Additional items
EPS (Basic) -1.39-0.47-0.59-0.64-0.64-0.75-0.68-0.78-0.82-0.65-0.72-0.67-0.70-0.70-0.69-0.78-0.92-0.95-0.82-0.92-0.71-0.43
EPS (Weighted Average and Diluted) -1.39-0.47-0.59-0.64-0.64-0.75-0.68-0.78-0.82-0.65-0.72-0.67-0.70-0.70-0.69-0.78-0.92-0.95-0.82-0.92-0.71-0.43
Shares Outstanding (Weighted Average) 1.71M1.62M1.90M12.25M35.45M21.34M35.65M35.75M35.91M35.85M36.12M36.17M46.80M42.02M56.06M59.17M59.69M58.72M60.18M60.38M60.73M60.54M61.22M61.39M61.41M
Shares Outstanding (Diluted Average) 1.71M1.62M1.90M12.25M35.45M21.34M35.65M35.75M35.91M35.85M36.12M36.17M46.80M42.02M56.06M59.17M59.69M58.72M60.18M60.38M60.73M60.54M61.22M61.39M61.41M
EBITDA 11.09M-17.09M-16.52M-19.04M-22.84M-22.84M-27.05M-24.69M-28.85M-29.86M-31.81M-34.56M-36.92M-42.10M-41.15M-38.86M-47.79M-55.98M-56.30M-50.26M-56.33M-43.46M-26.27M
Interest Expenses 0.17M0.30M0.32M0.31M0.32M0.32M0.32M0.45M0.87M0.88M0.83M0.80M0.81M0.81M